The groundbreaking ceremony for Zhejiang Lingyu Pharmaceutical Co., Ltd.'s (Lingyu Pharma) advanced complex injection project took place on September 15th in Taizhou, Zhejiang Province. Key figures including Xiao Weihong, Chairman and President of Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Pharma), Chen Yunhua, Chairman of Zhejiang Sundo Drug Delivery Technology Co., Ltd. (Sundo), Zhang Hongyao, Director and Executive Vice President of Sundo and Chairman of Lingyu Pharma, Jiang Ling, Senior Vice President of Hisun Pharma and Vice Chairman of Lingyu Pharma, and Zhang Ping, General Manager of Lingyu Pharma, attended the ceremony and jointly shoveled soil to mark the official launch of this initiative. This project is designed to spearhead the domestic breakthrough for high-end complex injections.

Complex injections, often hailed as the most challenging achievement in pharmaceutical formulation, encompass advanced dosage forms like microspheres, liposomes, and long-acting sustained-release preparations. They represent a critical gateway for the pharmaceutical industry to ascend the global value chain. The journey from lab to clinic is fraught with hurdles, including formulation design, process scale-up, and sterile assurance. For years, this market has been largely dominated by a handful of multinational corporations, leading to a scarcity of high-quality clinical options and creating a vast opportunity for domestic substitution. Building a self-reliant, internationally compliant industrial chain for complex injections is both an industry trend and a crucial mission for local pharmaceutical companies.

Lingyu Pharma was established in December 2025 as a joint venture between Hisun Pharma and Sundo. Hisun Pharma, with decades of roots in Taizhou, brings extensive experience in industrial transformation, market development, and international operations. Sundo specializes in high-end complex formulations, possessing mature, continuous, and linearly scalable core processes. The partnership aims to create a seamless, internationally standardized production base that connects laboratory R&D, large-scale manufacturing, and global clinical commercialization. This groundbreaking signifies a major step from agreement to action, marking a key advance in breaking the monopoly in domestic high-end complex injections.

In his address, Zhang Ping, General Manager of Lingyu Pharma, stated the company's core philosophy: to pursue the difficult but correct path and transform this challenge into a passport for Chinese pharmaceuticals to go global. He emphasized that true internationalization is not about low prices but about world-class quality and standards. Lingyu Pharma is committed to prioritizing R&D, treating quality as its lifeblood, and navigating by compliance to build a strong reputation for Chinese pharmaceutical quality.

Chen Yunhua, Chairman of Sundo, highlighted Lingyu Pharma's clear strategic positioning: to be deeply rooted locally, integrate with the regional pharmaceutical ecosystem, and answer whether Chinese pharmaceuticals can secure their place on the global stage through advanced formulations. He noted that China's pharmaceutical industry is at a pivotal moment, transitioning from following to running alongside global leaders. Advanced formulations represent the most promising area for a breakthrough. Lingyu Pharma's facility is being designed to international cGMP standards from day one, with the goal of bringing 'Made in China' high-end injections into mainstream global markets. He clarified that Sundo's involvement is not a mere financial investment but a commitment to the industry, pledging full support of its formulation expertise, scale-up knowledge, equipment, and registration capabilities to help Lingyu Pharma move forward swiftly and steadily.

In his concluding remarks, Xiao Weihong, Chairman and President of Hisun Pharma, framed the journey from domestic replacement to global supply as an industrial campaign for China's voice in the pharmaceutical world. Hisun Pharma will leverage its full resource chain to empower Lingyu Pharma and build a fast track for its global ambitions. The project must set high standards to create a benchmark facility, focus intensely on developing hardcore products by accelerating the translation of cutting-edge formulations into therapies with differentiated clinical value, and strategically target the global market to establish a strong brand for high-end complex injections 'Made in China.'

At an auspicious morning hour, the official soil-turning ceremony commenced. Principal guests from Hisun Pharma, Sundo, and Lingyu Pharma, holding gilded shovels, positioned themselves around the cornerstone to jointly break ground. The event was marked by celebratory salutes, flying ribbons, and resounding applause. Following the ceremony, all attendees gathered for a group photo to commemorate the milestone.

This groundbreaking lays the foundation for future success. It represents more than just the start of construction; it is a formal declaration of intent for domestically produced high-end complex injections to enter the global premium market. With the combined strength of Hisun Pharma and Sundo, Lingyu Pharma is poised to collaborate with all partners to build this project into one of industry significance, successfully navigating the path to internationalization and demonstrating to the world that high-end injections from China are trustworthy. Other attendees included Wu Jian, Vice Chairman of Sundo and Director of Lingyu Pharma; Jiang Chaojun, Director and President of Sundo and Director of Lingyu Pharma; Yang Zhiqing, Senior Vice President of Hisun Pharma; Zhou Houjiang, Party Committee Member of Hisun Pharma and Dean of its Innovative Drug Research Institute; Huang Huifeng, Director and Senior Vice President of Sundo; Lin Qiao, Director and Deputy General Manager of Lingyu Pharma; and Xu Hui, Assistant President of Hisun Pharma and Director of Sundo, along with other department heads from both parent companies.